Patrys Secures Ethics Approval for Phase 1A Trial of RLS-2202 with Dosing Set for Q3
Patrys has cleared a key regulatory hurdle with Human Research Ethics Committee approval for its Phase 1A clinical trial of RLS-2202, aiming to start dosing healthy volunteers this quarter.
- HREC approval obtained for Phase 1A trial of RLS-2202
- Trial to assess safety, tolerability, and pharmacokinetics in healthy volunteers
- Clinical site activation and participant recruitment underway at CMAX
- First dosing expected within the current quarter
- Sequential dose-escalation design with independent safety review
Ethics Approval Clears Path for Phase 1A Trial
Patrys Limited (ASX:PAB) has secured Human Research Ethics Committee (HREC) approval to initiate its Phase 1A clinical trial of RLS-2202, marking a pivotal regulatory milestone. The approval, granted by Bellberry on 27 August 2026, allows the company to proceed with testing the safety, tolerability, and pharmacokinetics of its injectable RLS-2202 in healthy adult volunteers.
The Phase 1A study is a bridging trial designed to evaluate intravenous and oral administration of RLS-2202, with a sequential dose-escalation approach. Progression between dosing cohorts will be overseen by an independent Safety Review Committee to ensure participant safety and scientific rigour.
Trial Execution and Next Steps
With ethics approval in hand, Patrys is advancing clinical site activation and participant screening at CMAX in South Australia. The company expects to commence first participant dosing within the current quarter, following completion of remaining regulatory steps including notification to the Therapeutic Goods Administration under the Clinical Trial Notification scheme and registration on the Australian New Zealand Clinical Trials Registry.
CEO Dr Samantha South emphasised the significance of this development, stating, "We are pleased to have received ethics approval for our Phase 1A clinical trial. This is a significant step forward and reflects the strong progress being made across the program." The company is focused on recruiting participants and generating data to guide subsequent clinical stages.
RLS-2202 Targets Unmet Need in Delirium Treatment
RLS-2202 is positioned as an injectable therapy targeting delirium, a condition with substantial unmet medical need. The Phase 1A trial will provide critical dosing information to inform later-stage development and supports Patrys' broader strategy to advance its proprietary quetiapine formulation through an accelerated regulatory pathway.
Patrys continues to collaborate closely with its manufacturing, bioanalytical, and clinical partners to ensure the trial meets the highest standards. This progress builds on previous announcements detailing partnerships with CMAX and Alithia Life Sciences to lead trial operations and manufacturing readiness.
Bottom Line?
Patrys’ successful ethics approval sets the stage for imminent clinical trial activity, but the real test lies ahead in translating early safety and pharmacokinetic data into a viable delirium treatment.
Questions in the middle?
- How quickly will Patrys progress through participant recruitment and dosing milestones?
- What safety and pharmacokinetic signals will emerge from the Phase 1A trial?
- How will these early data influence the design and timeline of subsequent clinical phases?
